Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 9/20 | 0.40 |
| ▸ | MMP13 | P45452 | 3/20 | 0.40 |
| ▸ | MMP2 | P08253 | 8/20 | 0.40 |
| ▸ | MMP3 | P08254 | 6/20 | 0.40 |
| ▸ | BMP1 | P13497 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2796971 | 1.00 | MMP1 (0.40) | MMP1MMP13MMP2MMP3BMP1 | |
| SCHEMBL2794578 | 0.88 | MMP1 (0.41) | MMP1MMP13MMP2MMP3CTSS | |
| SCHEMBL2794582 | 0.86 | MMP1 (0.40) | MMP1MMP13MMP2MMP3CCR5 | |
| SCHEMBL2794584 | 0.86 | MMP1 (0.40) | MMP1MMP13MMP2MMP3CCR5 | |
| SCHEMBL5494014 | 0.79 | MMP1 (0.44) | MMP1MMP13MMP2MMP3BMP1 | |
| SCHEMBL5494009 | 0.79 | MMP1 (0.44) | MMP1MMP13MMP2MMP3BMP1 | |
| SCHEMBL2795249 | 0.77 | HTR2A (0.47) | CCR5HTR2A | |
| SCHEMBL2797087 | 0.77 | THRB (0.39) | MMP1MMP13CTSS | |
| Hydrochloric Acid SCHEMBL2795250 | 0.76 | HTR2A (0.46) | CCR5HTR2A | |
| Hydrochloric Acid SCHEMBL2794028 | 0.76 | HTR2A (0.46) | CCR5HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168421-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168421-A1 | A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF | PDF, PEPD, DPEP1 | MMP1 2274/4885MMP13 2075/4885MMP2 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.